Preventing adverse drug effects and other major safety issues largely depends on the accuracy of your Quality Management System (QMS). It’s common to have many questions when setting up a QMS and entering QMS remediation, especially when dealing with Pharmacovigilance (PV). Here we try to address a few of them. Let’s probe how PV QMS remediation addresses real inspection findings beyond documentation.
Does the PV QMS remediation address previous inspection findings?
Yes. PV QMS remediation addresses previous inspection findings. It maps each finding/observation to a measurable CAPA and the root cause. For example, delays in CAPA, weak/poor PV audits, and poor control over PSMF. Procedures, training, tools, and governance are redesigned to prevent recurrence, with KPIs such as CAPA closure time, audit completion, and PSUR timeliness tracked and trended to sustain improvement.
What kind of changes strengthen PV QMS around audits, deviations, and documentation?
Audit programmes in PV are conducted at risk-based frequencies based on product risk, data volumes, and past findings. Using standardized templates and 100% root-cause analysis with proper escalation setup helps build deviation/CAPA workflows. To further strengthen PV QMS, it is recommended to develop SOPs, including procedural documents and training materials.
How does QMS remediation bolster ongoing safety evaluation and risk management?
The elements of PV QMS directly integrate with key pharmacovigilance processes, such as PSUR/PBRER production, RMP implementation, signal management, and literature monitoring. It, in a way, ensures consistent oversight of safety. On the other hand, the governance structure enforces accountability with mandatory regular safety review meetings, traceable decisions, highlighted dashboards (for late deliverables), and action follow-through. For example, label updates, aRMM roll-out, etc.
What evidence integrates vendor/partner PV activities into the remediated QMS?
Quality agreements with safety-critical PV partners (such as case processors and call centers) define responsibilities to ensure compliance and oversight. The duties may include PV roles, timelines, data flow, audits, & CAPA expectations. Under the detailed PV contracts, vendors’ work is documented accurately and tracked via the QMS, with inspections to audit it. It, in fact, ensures no safety gaps.
When should a formal PV QMS remediation initiative be triggered?
One can initiate formal PV QMS remediation whenever there are significant/critical PV findings across QMS, CAPA, risk management, PSUR/signal issues, or when CAPAs don’t work. It will help vendors/partners proactively address systemic weaknesses, such as delays or process inconsistencies, well before regulators flag them.
Do you have any further questions about the QMS remediation in Pharmacovigilance? Are you challenged with QMS remediation activities? Ensure you select an expert regulatory consulting firm and/or a CRO.
Comments are closed